CRH Medical (CRHM) Announces Quarterly Earnings Results

CRH Medical logo CRH Medical (NYSEAMERICAN:CRHM) released its quarterly earnings results on Wednesday, March 13th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.02, Morningstar.com reports. The firm had revenue of $32.02 million for the quarter, compared to the consensus estimate of $31.40 million.

Shares of NYSEAMERICAN:CRHM opened at $2.70 on Friday. CRH Medical has a 12-month low of $2.40 and a 12-month high of $4.50.

A number of research analysts recently issued reports on the company. Zacks Investment Research upgraded CRH Medical from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research note on Tuesday, March 19th. TD Securities reiterated a “buy” rating on shares of CRH Medical in a research note on Tuesday, January 8th. Finally, Clarus Securities reiterated a “buy” rating on shares of CRH Medical in a research note on Wednesday, March 20th.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Ativo Capital Management LLC lifted its holdings in CRH Medical by 7.1% in the 3rd quarter. Ativo Capital Management LLC now owns 300,079 shares of the company’s stock worth $1,185,000 after purchasing an additional 20,002 shares in the last quarter. Two Sigma Advisers LP lifted its holdings in CRH Medical by 12.6% in the 4th quarter. Two Sigma Advisers LP now owns 220,300 shares of the company’s stock worth $675,000 after purchasing an additional 24,700 shares in the last quarter. ClariVest Asset Management LLC purchased a new position in CRH Medical in the 3rd quarter worth approximately $154,000. Acadian Asset Management LLC purchased a new stake in shares of CRH Medical during the 3rd quarter worth approximately $354,000. Finally, Beutel Goodman & Co Ltd. raised its holdings in shares of CRH Medical by 3.5% during the 4th quarter. Beutel Goodman & Co Ltd. now owns 5,127,100 shares of the company’s stock worth $1,570,000 after acquiring an additional 171,970 shares in the last quarter.

CRH Medical Company Profile

CRH Medical Corporation provides various products and services to gastroenterologists for the treatment of gastrointestinal diseases in the United States, Canada, and internationally. It offers CRH O’Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid.

Further Reading: The Structure of a Futures Contract Earnings History for CRH Medical (NYSEAMERICAN:CRHM) Receive News & Ratings for CRH Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CRH Medical and related companies with MarketBeat.com’s FREE daily email newsletter .

Click Here to Continue...